{"disease":{"id":"advanced-non-squamous-non-small-cell-lung-cancer","name":"advanced non squamous non small cell lung cancer"},"drugs":{"marketed":[{"drug_id":"telisotuzumab","indication_name":"locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Emrelis","generic_name":"TELISOTUZUMAB","company_name":"Abbvie Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":53,"revenue":null,"mechanism":"Emrelis binds to the c-Met protein on cancer cells, blocking its growth-promoting signals."}],"pipeline":[{"drug_id":"pf-06439535-cn","indication_name":"Advanced non-squamous non-small-cell lung cancer (NSCLC)","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06439535 (CN)","generic_name":"pf-06439535-cn","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Not publicly disclosed; presumed to be VEGF pathway or related angiogenic target based on clinical trial design","drug_class":"Selective pathway inhibitor; presumed anti-angiogenic agent","quality_score":null,"revenue":null,"mechanism":"Selective inhibitor blocking proteins that drive abnormal cell growth and division in cancer cells."}],"offLabel":[],"totalMarketed":1,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT07485166","title":"Emulation of the CheckMate 017/057 (NCT01642004 and NCT01673867) Trials Using Specialty Oncology Electronic Health Records Databases","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":810,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT04416035","title":"A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":608,"lead_sponsor_name":"Zhejiang Teruisi Pharmaceutical Inc.","has_results":false},{"nct_id":"NCT05132413","title":"A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":561,"lead_sponsor_name":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT06416410","title":"JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":392,"lead_sponsor_name":"Allist Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT04439890","title":"A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":369,"lead_sponsor_name":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","has_results":false},{"nct_id":"NCT06311721","title":"A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":315,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT04181060","title":"Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05652868","title":"Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":227,"lead_sponsor_name":"Mythic Therapeutics","has_results":false},{"nct_id":"NCT07405086","title":"Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":160,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT05269381","title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04137588","title":"Efficacy and Safety of Use of Platinum Based Doublet Chemotherapy Plus Antiangiogenesis and Immune Checkpoint Inhibitors in Patients With Advanced Non-squamous Non-small Cell Lung Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":126,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT05086692","title":"A Beta-only IL-2 ImmunoTherapY Study","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":115,"lead_sponsor_name":"Medicenna Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04974957","title":"Study of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":71,"lead_sponsor_name":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT05648071","title":"First-Line Treatment for Advanced Non-squamous Non-Small-Cell Lung Cancer With Negative Driver Gene: a Single-center, Single-Arm Trial","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Qianfoshan Hospital","has_results":false},{"nct_id":"NCT04173507","title":"Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":true},{"nct_id":"NCT04007744","title":"Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":36,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05017025","title":"Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":32,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02520778","title":"Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04959981","title":"A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Erasca, Inc.","has_results":false},{"nct_id":"NCT02535325","title":"Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04971187","title":"Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT03190239","title":"Efficacy and Safety of Maintenance Apatinib Combined With Pemetrexed in Advanced Non-squamous Non-small Cell Lung Cancer Patients","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Xinqiao Hospital of Chongqing","has_results":false}],"total":22},"guidelines":[],"source":"Drug Landscape verified database"}